Name: NEKTAR THERAPEUTICS (NKTR) Stock
Brand: NEKTAR THERAPEUTICS
Rating: 5 (3 reviews)

NKTR Latest News, Press Relases and Analysis

All

Press Releases

12 hours ago - By: Nektar Therapeutics

REZOLVE-AA Phase 2b Study of Rezpegaldesleukin Establishes Proof-of-Concept in Patients with Severe-to-Very-Severe Alopecia Areata

a day ago - By: Nektar Therapeutics

Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025

8 days ago - By: Zacks Investment Research

Here's Why Nektar Therapeutics (NKTR) is a Great Momentum Stock to Buy

11 days ago - By: Nektar Therapeutics

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

15 days ago - By: Zacks Investment Research

Wall Street Analysts Believe Nektar (NKTR) Could Rally 64.53%: Here's is How to Trade

a month ago - By: Benzinga - Mentions: STVN PODD AMRK SOLV ...

Earnings Scheduled For November 6, 2025

4 months ago - By: The Motley Fool

Nektar (NKTR) Q2 Revenue Falls 52%

4 months ago - By: Benzinga - Mentions: GSAT PGY ADV REAL ...

Earnings Scheduled For August 7, 2025

a month ago - By: The Motley Fool - Mentions: CDTX BMRN MRK

Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know.

a month ago - By: Zacks Investment Research

Does Nektar (NKTR) Have the Potential to Rally 62.75% as Wall Street Analysts Expect?

a month ago - By: Nektar Therapeutics

New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting

a month ago - By: Zacks Investment Research - Mentions: LLY ANIP ACAD

Nektar Therapeutics Q3 Loss Narrower Than Expected, Revenues Rise Y/Y

a month ago - By: Zacks Investment Research - Mentions: MDWD

Nektar Therapeutics (NKTR) Reports Q3 Loss, Beats Revenue Estimates

a month ago - By: Nektar Therapeutics

Nektar Therapeutics Reports Third Quarter 2025 Financial Results

a month ago - By: Zacks Investment Research - Mentions: GRDN

Guardian Pharmacy Services (GRDN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

2 months ago - By: Nektar Therapeutics

Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

2 months ago - By: Zacks Investment Research - Mentions: OABI

Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

2 months ago - By: Nektar Therapeutics

Nektar to Announce Financial Results for the Third Quarter on Thursday, November 6, 2025, After Close of U.S.-Based Financial Markets

2 months ago - By: Nektar Therapeutics

Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting

3 months ago - By: Zacks Investment Research - Mentions: REGN SNY LLY

NKTR Shares Surge 38.2% in a Week: Here's What You Should Know

3 months ago - By: Nektar Therapeutics

Nektar Therapeutics to Participate in Two Investor Conferences in September

4 months ago - By: Zacks Investment Research - Mentions: LLY CRMD IMCR

Nektar Q2 Loss Narrower Than Expected, Revenues Fall Y/Y

4 months ago - By: Zacks Investment Research - Mentions: MDWD

Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates

4 months ago - By: Nektar Therapeutics

Nektar Therapeutics Reports Second Quarter 2025 Financial Results

4 months ago - By: Zacks Investment Research - Mentions: RIGL

Rigel Pharmaceuticals (RIGL) Q2 Earnings and Revenues Surpass Estimates

4 months ago - By: Zacks Investment Research - Mentions: LLY CRMD AMRX

NEKTAR THERAPEUTICS (NKTR) Stock News

NKTR Latest News, Press Relases and Analysis

REZOLVE-AA Phase 2b Study of Rezpegaldesleukin Establishes Proof-of-Concept in Patients with Severe-to-Very-Severe Alopecia Areata

Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025

Here's Why Nektar Therapeutics (NKTR) is a Great Momentum Stock to Buy

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wall Street Analysts Believe Nektar (NKTR) Could Rally 64.53%: Here's is How to Trade

Earnings Scheduled For November 6, 2025

Nektar (NKTR) Q2 Revenue Falls 52%

Earnings Scheduled For August 7, 2025

Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know.

Does Nektar (NKTR) Have the Potential to Rally 62.75% as Wall Street Analysts Expect?

New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting

Nektar Therapeutics Q3 Loss Narrower Than Expected, Revenues Rise Y/Y

Nektar Therapeutics (NKTR) Reports Q3 Loss, Beats Revenue Estimates

Nektar Therapeutics Reports Third Quarter 2025 Financial Results

Guardian Pharmacy Services (GRDN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Nektar to Announce Financial Results for the Third Quarter on Thursday, November 6, 2025, After Close of U.S.-Based Financial Markets

Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting

NKTR Shares Surge 38.2% in a Week: Here's What You Should Know

Nektar Therapeutics to Participate in Two Investor Conferences in September

Nektar Q2 Loss Narrower Than Expected, Revenues Fall Y/Y

Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates

Nektar Therapeutics Reports Second Quarter 2025 Financial Results

Rigel Pharmaceuticals (RIGL) Q2 Earnings and Revenues Surpass Estimates

Nektar Gears Up to Report Q2 Earnings: What's in the Cards?